Innovation1 Biotech Inc. (IVBT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -52.69 Thousand USD | 97.93% |
| 2022 | -2.54 Million USD | -153587.76% |
| 2021 | 1659.00 USD | 193.05% |
| 2020 | -1783.00 USD | 96.44% |
| 2019 | -50.09 Thousand USD | 22.04% |
| 2018 | -64.25 Thousand USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 FY | -52.69 Thousand USD | 97.93% |
| 2023 Q2 | -261.00 USD | 99.5% |
| 2023 Q3 | -262.00 USD | -0.38% |
| 2023 Q4 | -262.00 USD | 0.0% |
| 2023 Q1 | -51.91 Thousand USD | 93.19% |
| 2022 Q1 | 1659.00 USD | 295.87% |
| 2022 FY | -2.54 Million USD | -153587.76% |
| 2022 Q4 | -762.78 Thousand USD | 15.3% |
| 2022 Q3 | -900.52 Thousand USD | -1.98% |
| 2022 Q2 | -883.04 Thousand USD | -53327.73% |
| 2021 FY | 1659.00 USD | 193.05% |
| 2021 Q3 | -22.00 USD | 94.32% |
| 2021 Q2 | -387.00 USD | -123.33% |
| 2021 Q1 | 1659.00 USD | -99.22% |
| 2021 Q4 | -847.00 USD | -3750.0% |
| 2020 Q3 | -150.24 Thousand USD | -149.92% |
| 2020 Q2 | -60.11 Thousand USD | -2046.3% |
| 2020 Q4 | 211.37 Thousand USD | 240.69% |
| 2020 Q1 | -2801.00 USD | 95.81% |
| 2020 FY | -1783.00 USD | 96.44% |
| 2019 Q3 | 11.33 Thousand USD | -67.05% |
| 2019 Q2 | 34.39 Thousand USD | 218.86% |
| 2019 Q1 | -28.93 Thousand USD | 45.74% |
| 2019 FY | -50.09 Thousand USD | 22.04% |
| 2019 Q4 | -66.88 Thousand USD | -690.19% |
| 2018 Q4 | -53.32 Thousand USD | -2589.16% |
| 2018 Q2 | -10.1 Thousand USD | -973.12% |
| 2018 Q1 | 1157.00 USD | 0.0% |
| 2018 FY | -64.25 Thousand USD | 0.0% |
| 2018 Q3 | -1983.00 USD | 80.37% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 131.258% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 78.921% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 90.436% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 70.394% |
| Better Therapeutics, Inc. | -2.72 Million USD | 98.069% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 96.195% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 112.467% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 99.77% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | 94.841% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 99.257% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 79.653% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 98.115% |
| Molecular Templates, Inc. | 50.39 Million USD | 100.105% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 55.825% |
| NexImmune, Inc. | -1.02 Million USD | 94.859% |
| Orgenesis Inc. | -5.72 Million USD | 99.08% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 99.795% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -1045.36% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 100.179% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 89.208% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 77.285% |
| Trevena, Inc. | 1.45 Million USD | 103.622% |
| Vaxxinity, Inc. | -2.23 Million USD | 97.641% |
| Vaccinex, Inc. | -16 Million USD | 99.671% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 89.289% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 553.902% |